Laekna Inc
HKEX:2105
Laekna Inc
Laekna, Inc. engages in the clinical stage research and development of biopharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2023-06-29. The firm is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The firm's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The firm mainly conducts its businesses in China, the United States, Europe and South Korea.
Laekna, Inc. engages in the clinical stage research and development of biopharmaceutical products. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2023-06-29. The firm is mainly engaged in the research and development of drug candidates for monotherapy and combination therapy, focusing on the treatment of various cancers and liver fibrosis diseases. The firm's main product pipelines include LAE002 and LAE001. The LAE002 is an adenosine triphosphate (ATP) competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, breast cancer and PD-1/PD-L1 drug-resistant solid tumors. The LAE001 is an androgen synthesis inhibitor that simultaneously inhibits cytochrome P450 family 17 subfamily A member 1 (CYP17A1) and cytochrome P450 family 11 subfamily B member 2 (CYP11B2) for the treatment of prostate cancer. The firm mainly conducts its businesses in China, the United States, Europe and South Korea.
